[Use of a GnRH analogue in the treatment of certain forms of endometrial hyperplasia associated with menometrorrhagia].
Hyperestrogenism is a powerful factor inducing the development of endometrial hyperplasia that in its turn may represent the first step in the natural history of endometrial carcinoma. During menopause it is possible to have a condition to relative hyperestrogenism induced by a residual hormonal activity and by aromatisation of androgens in the adipose tissue. Therapeutical approach in this pathology aims to control hyperplastic development of the endometrial mucosa and to exclude menometrorrhagia. This study has been performed according to an open uncontrolled design in 14 women (4 menopausal women) with abnormal uterine bleeding and hysteroscopic endometrial cystic or adenomatous hyperplasia. At the beginning and at the end of treatment all patients underwent routine biohumoral blood-tests, hysteroscopy and diagnostic curretage. The GnRH analogue (tryptorelin) 3.75 mg 1 ampoule i.m. every 28 days was administered during a 6-month treatment cycle. At the end of therapy bleeding had disappeared in all menopausal women; in the premenopausal group 8 patients have shown a normal menstrual cycle while 2 are still amenorrhoic. The final hysteroscopic evaluation displayed atrophic endometrium in 9 patients and simple proliferative endometrium in 5 cases. Safety was excellent: 3 cases of slight increase of systolic blood pressure and 1 case of slight increase of weight took place. Our results demonstrate therapeutic efficacy of GnRH analogues in the treatment of endometrial hyperplasia with menometrorrhagia either in premenopausal or menopausal women.
Bonfirraro
G
G
Università di Firenze.
Sanna
B
B
De Marco
A
A
Chieffi
O
O
Bonfirraro
P P
PP
Orlando
V
V
D000368:Aged; D004305:Dose-Response Relationship, Drug; D004714:Endometrial Hyperplasia / Q000150:complications / Q000188:drug therapy*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008593:Menopause; D008595:Menorrhagia / Q000209:etiology / Q000517:prevention & control; D008796:Metrorrhagia / Q000209:etiology / Q000517:prevention & control; D008875:Middle Aged; D017697:Premenopause; D017329:Triptorelin Pamoate / Q000008:administration & dosage / Q000627:therapeutic use*
D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone
Impiego di un analogo del GnRH nel trattamento di alcune forme di patologia iperplastica endometriale associate a menometrorragia.